EP4704898A2 - Menschliche monoklonale antikörper, die pad4 verstärken, zur verwendung bei autoimmunkrankheiten - Google Patents

Menschliche monoklonale antikörper, die pad4 verstärken, zur verwendung bei autoimmunkrankheiten

Info

Publication number
EP4704898A2
EP4704898A2 EP24803963.8A EP24803963A EP4704898A2 EP 4704898 A2 EP4704898 A2 EP 4704898A2 EP 24803963 A EP24803963 A EP 24803963A EP 4704898 A2 EP4704898 A2 EP 4704898A2
Authority
EP
European Patent Office
Prior art keywords
antibodies
antibody
pad4
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24803963.8A
Other languages
English (en)
French (fr)
Inventor
Felipe Andrade
Erika DARRAH
Jing Shi
Antony Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP4704898A2 publication Critical patent/EP4704898A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP24803963.8A 2023-05-05 2024-05-02 Menschliche monoklonale antikörper, die pad4 verstärken, zur verwendung bei autoimmunkrankheiten Pending EP4704898A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363464249P 2023-05-05 2023-05-05
PCT/US2024/027401 WO2024233251A2 (en) 2023-05-05 2024-05-02 Human monoclonal antibodies that enhance pad4 for use in autoimmune diseases

Publications (1)

Publication Number Publication Date
EP4704898A2 true EP4704898A2 (de) 2026-03-11

Family

ID=93430953

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24803963.8A Pending EP4704898A2 (de) 2023-05-05 2024-05-02 Menschliche monoklonale antikörper, die pad4 verstärken, zur verwendung bei autoimmunkrankheiten

Country Status (2)

Country Link
EP (1) EP4704898A2 (de)
WO (1) WO2024233251A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3541841T3 (da) * 2016-11-18 2024-10-21 Servier Lab Anti-PD-1-antistoffer og sammensætninger
US11807663B2 (en) * 2018-02-01 2023-11-07 Innovent Biologics (Suzhou) Co., Ltd. Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
CA3136281C (en) * 2019-05-30 2024-06-25 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2

Also Published As

Publication number Publication date
WO2024233251A3 (en) 2025-02-20
WO2024233251A2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
US20260116998A1 (en) Novel anti-pad4 antibody
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
US11427642B2 (en) Anti-BCMA heavy chain-only antibodies
JP5814790B2 (ja) デングウイルス中和抗体およびその使用
JP2020505001A (ja) 抗ｂｃｍａ重鎖のみ抗体
RS62749B1 (sr) Anti-c5 antitela i načini njihove upotrebe
US10717785B2 (en) Binding molecules that bind human complement factor C2 and uses thereof
RS57324B1 (sr) Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
RS60031B1 (sr) Humanizovana anti-tau(ps422) antitela i načini upotrebe
EA036756B1 (ru) Антитела к с5 и способы их применения
US20230220093A1 (en) Multispecific Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof
US11104722B2 (en) Immunogenetic restriction on elicitation of antibodies
RS60795B1 (sr) Vezujući molekuli specifični za il-21 i njihove upotrebe
WO2019131769A1 (ja) 新規抗ｐａｄ４抗体
JP2023139243A (ja) 抗ペリオスチン抗体及びその使用
EP3816289A1 (de) Neuartiger anti-pad2-antikörper
TW202208427A (zh) 人源化抗ｃ５ａ抗體
US20250236683A1 (en) Composition and method for inhibiting fibrosis
EP4704898A2 (de) Menschliche monoklonale antikörper, die pad4 verstärken, zur verwendung bei autoimmunkrankheiten
WO2024233254A2 (en) Human monoclonal antibodies for treating subjects suffering from pulmonary fibrosis
RU2830232C2 (ru) Методы профилактики и лечения сердечных заболеваний
RU2789788C2 (ru) Антитела к с5 и способы их применения
TW202517673A (zh) 與Ｃ３ｂＢｂ結合之抗體
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra
EA041304B1 (ru) СПОСОБ ПОЛУЧЕНИЯ АНТИ-C5 АНТИТЕЛА С БОЛЕЕ ВЫСОКОЙ АФФИННОСТЬЮ ПРИ pH 7,4, ЧЕМ ПРИ pH 5,8 (ВАРИАНТЫ)

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR